The expression of the adenosine pathway markers CD39 and CD73 in salivary gland carcinomas harbors the potential for novel immune checkpoint inhibition.
Adenosine signaling
CD39
CD73
Immunotherapy
SGC
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
29
05
2022
accepted:
13
07
2022
medline:
5
7
2023
pubmed:
29
7
2022
entrez:
28
7
2022
Statut:
ppublish
Résumé
In salivary gland carcinomas (SGC), there is only a small fraction of entities that appears to profit from immune checkpoint inhibition (ICI). Recent findings connected the activation of adenosine-signaling with a tolerogenic microenvironment. Therefore, the inhibition of adenosine pathway markers (CD39 and/or CD73) can augment ICI and/or display a novel immunotherapeutic strategy beyond ICI. Here, we assessed the immuno-histochemical expression of CD39 and CD73 across a wide spectrum of SGCs. In total, 114 patients with SGCs consecutively diagnosed between 2001 and 2021 were assessed for clinicopathological baseline characteristics and underwent confirmatory histopathological review. Immunohistochemical expression levels of CD39 and CD73 were assessed by applying the tumor proportion score (TPS) and the immune proportional score (IPS) comparable to PD-L1 expression analysis in routine clinical practice. Additionally, findings were correlated with PD-L1 expression levels. The median age was 60.6 and 51.8% patients were female. The cohort covered a spectrum of eight distinct entities. Advanced-stage disease (UICC/AJCC III/IVA-IVC) at initial diagnosis was present in the majority of patients (64/114). Immunohistochemical staining revealed positivity for CD39 and CD73 in 48.2% and 21.1% on tumor cells (TPS ≥ 1%) as well as 46.4% and 42.9% within the immune cell infiltrate (IPS ≥ 1%), respectively. Further comparative analyses revealed immune-cold entities such adenoid cystic carcinoma (AdCC), immune-hot tumors such as adenocarcinoma, not otherwise specified (AC (NOS)) and entities with intermediate immunologic features such as acinic cell carcinoma (ACC). Current results indicate entity-specific adenosine signaling signatures. These findings suggest that the adenosine pathway plays a decisive role in tumor immunity among the major spectrum of SGCs. Targeting the adenosine pathway might pose a promising therapeutic option for selected entities.
Sections du résumé
BACKGROUND
BACKGROUND
In salivary gland carcinomas (SGC), there is only a small fraction of entities that appears to profit from immune checkpoint inhibition (ICI). Recent findings connected the activation of adenosine-signaling with a tolerogenic microenvironment. Therefore, the inhibition of adenosine pathway markers (CD39 and/or CD73) can augment ICI and/or display a novel immunotherapeutic strategy beyond ICI. Here, we assessed the immuno-histochemical expression of CD39 and CD73 across a wide spectrum of SGCs.
METHODS
METHODS
In total, 114 patients with SGCs consecutively diagnosed between 2001 and 2021 were assessed for clinicopathological baseline characteristics and underwent confirmatory histopathological review. Immunohistochemical expression levels of CD39 and CD73 were assessed by applying the tumor proportion score (TPS) and the immune proportional score (IPS) comparable to PD-L1 expression analysis in routine clinical practice. Additionally, findings were correlated with PD-L1 expression levels.
RESULTS
RESULTS
The median age was 60.6 and 51.8% patients were female. The cohort covered a spectrum of eight distinct entities. Advanced-stage disease (UICC/AJCC III/IVA-IVC) at initial diagnosis was present in the majority of patients (64/114). Immunohistochemical staining revealed positivity for CD39 and CD73 in 48.2% and 21.1% on tumor cells (TPS ≥ 1%) as well as 46.4% and 42.9% within the immune cell infiltrate (IPS ≥ 1%), respectively. Further comparative analyses revealed immune-cold entities such adenoid cystic carcinoma (AdCC), immune-hot tumors such as adenocarcinoma, not otherwise specified (AC (NOS)) and entities with intermediate immunologic features such as acinic cell carcinoma (ACC).
CONCLUSION
CONCLUSIONS
Current results indicate entity-specific adenosine signaling signatures. These findings suggest that the adenosine pathway plays a decisive role in tumor immunity among the major spectrum of SGCs. Targeting the adenosine pathway might pose a promising therapeutic option for selected entities.
Identifiants
pubmed: 35902382
doi: 10.1007/s00432-022-04211-x
pii: 10.1007/s00432-022-04211-x
pmc: PMC10314850
doi:
Substances chimiques
Adenosine
K72T3FS567
Antigens, CD
0
B7-H1 Antigen
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3193-3208Informations de copyright
© 2022. The Author(s).
Références
Cancer. 1988 Dec 1;62(11):2313-9
pubmed: 3179947
Cancer Res. 2017 Sep 1;77(17):4697-4709
pubmed: 28652246
Cancers (Basel). 2020 Apr 03;12(4):
pubmed: 32260165
Curr Opin Pharmacol. 2020 Aug;53:66-76
pubmed: 32777746
J Immunother Cancer. 2020 Feb;8(1):
pubmed: 32098829
Lancet Oncol. 2011 Aug;12(8):815-24
pubmed: 21147032
Cancer Cell. 2016 Sep 12;30(3):391-403
pubmed: 27622332
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Nat Med. 2020 Jan;26(1):39-46
pubmed: 31873309
Histopathology. 2014 Dec;65(6):793-804
pubmed: 25040772
Am J Clin Oncol. 2018 Nov;41(11):1083-1088
pubmed: 29462123
Head Neck Pathol. 2017 Mar;11(1):48-54
pubmed: 28247228
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Exp Dent. 2019 Mar 01;11(3):e213-e218
pubmed: 31001389
Free Radic Biol Med. 1993 Dec;15(6):681-4
pubmed: 8138195
Immunotherapy. 2019 Aug;11(11):983-997
pubmed: 31223045
Cancer Lett. 2021 Aug 28;521:109-118
pubmed: 34464670
Cancer Immunol Immunother. 2021 Jul;70(7):1965-1976
pubmed: 33416944
BMC Cancer. 2021 Aug 6;21(1):899
pubmed: 34362344
Hum Pathol. 2017 Aug;66:10-12
pubmed: 28583885
Immunol Lett. 2019 Jan;205:25-30
pubmed: 29550257
Cancer Res. 1989 Jul 1;49(13):3702-7
pubmed: 2471588
Cancer Discov. 2019 Dec;9(12):1754-1773
pubmed: 31699796
CNS Drugs. 2014 May;28(5):455-74
pubmed: 24687255
Lancet Oncol. 2017 Nov;18(11):1483-1492
pubmed: 28967485
J Clin Oncol. 2022 Oct 10;40(29):3383-3393
pubmed: 35452273
Cell Rep. 2019 May 21;27(8):2411-2425.e9
pubmed: 31116985
J Hematol Oncol. 2019 Apr 11;12(1):37
pubmed: 30971294
Cancer Immunol Immunother. 2018 Aug;67(8):1271-1284
pubmed: 29923026
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
Cancer Immunol Res. 2020 Mar;8(3):356-367
pubmed: 31992567
Cancer Discov. 2020 Jan;10(1):40-53
pubmed: 31732494
Curr Treat Options Oncol. 2017 Jul;18(7):40
pubmed: 28555375
Nat Rev Clin Oncol. 2020 Oct;17(10):611-629
pubmed: 32514148
Crit Rev Oncol Hematol. 2022 Feb;170:103592
pubmed: 35026433
Nature. 2009 Sep 10;461(7261):282-6
pubmed: 19741708
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
Pathologe. 2018 Nov;39(6):498-519
pubmed: 30367225
Med Oncol. 2000 Nov;17(4):319-24
pubmed: 11114712
Cancer Res. 2010 Mar 15;70(6):2245-55
pubmed: 20179192
Immunol Rev. 2017 Mar;276(1):121-144
pubmed: 28258700
Oncoimmunology. 2017 Apr 21;6(6):e1320011
pubmed: 28680754